American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jul 2015
Fluoroquinolone Therapy for the Prevention of Multi-drug Resistant Tuberculosis in Contacts: a Cost-effectiveness Analysis.
Fluoroquinolone (FQN) therapy of latent tuberculosis infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversial. ⋯ In our model, FQN preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease as well as improved quality of life. FQN therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing MDR-TB was as low as 10%.